The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The new American College of Cardiology expert consensus includes a four-part staging system with a segment for “asymptomatic” ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January.

AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...